April, 2024
April 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  

Warning: Trying to access array offset on value of type bool in /var/www/vhosts/oncodaily.com/public_html/pub/themes/oncodailynews/single.php on line 25

Warning: Trying to access array offset on value of type bool in /var/www/vhosts/oncodaily.com/public_html/pub/themes/oncodailynews/single.php on line 26
Mar 4, 2024, 17:27

Piotr Wysocki: Anthracyclines must always be considered in the adjuvant treatment of breast cancer patients- final results of ABC trials

Piotr Wysocki, Professor of Medicine and Head of Department of Oncology at Jagiellonian University Hospital in Poland, shared on LinkedIn:

“The final results of the Anthracyclines in Early Breast Cancer (ABC) trials have just been published in Journal of Clinical Oncology by Geyer CE et al. The study’s primary endpoint was IDFS, with secondary endpoints including RFI and OS. An HR >1.18 was predefined as demonstrating inferiority, corresponding to an absolute difference of ≥2% in the 5-year IDFS rate of non-anthracycline chemotherapy (TC) relative to anthracycline-based chemotherapy (TaxAC). A population of 4181 patients was randomized in a 1:1 ratio to sequential TaxAC or to 6 cycles of TC (docetaxel+cyclophosphamide). With a median follow-up of 6.9 years on 4181 patients, the iDFS at 5 years was 85.1% in the nonanthracycline group vs 86.7% in the anthracycline group with HR for iDFS of 1.14 (80%CI 1.04-1.25). Thus, the noninferiority of nonanthracycline regimen was not confirmed.

The anthracycline regimens were clearly favored in the HR-negative subgroup. With HR for RFS of 1.90 (95% CI = 1.39–2.61, P < .0001) and for iDFS of 1.30 (95% CI = 1.02–1.67, P = .04),

No significant differences were observed in OS (HR=1.05, 95%CI 0.87-1.26).”

Source: Piotr Wysocki/LinkedIn